Abstracts tagged "Bone density"

Abstract Number: 1320 • ACR Convergence 2022
Performance of FRAX® Brazil and NOGG Methodology with and Without Bone Mineral Density upon Predicting Fractures on a Community-Dwelling Elderly Population with High Incidence of Osteoporotic Fractures: The São Paulo Ageing and Health (SPAH) Study
Thiago Q Freitas¹, Leonardo F G Olalla¹, Liliam Takayama¹, Valeria Caparbo², camille figueiredo², Luana Machado³, Diogo Domiciano⁴ and Rosa Pereira², ¹University of São Paulo, São Paulo, Brazil, ²Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: SPAH is a prospective cohort of ≥65-year-old community-dwelling elderly with high fracture risk (40.3/1,000 person-years in women and 30.6/1,000 in men for vertebral fractures…
Abstract Number: 1323 • ACR Convergence 2022
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
JOSE ELOY OLLER RODRIGUEZ¹, Elena Grau García², Samuel Leal Rodriguez³, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales², Francisco Miguel Ortiz Sanjuan⁷, José Ivorra Cortés², Inés Cánovas Olmos², Luis González Puig⁸, Isabel Martínez-Cordellat², Carmen Nájera Herranz⁷, Rosa Negueroles Albuixech², Elvira Vicens Bernabeu⁷, Alba Torrat Novés⁵, Daniel Ramos Castro² and José andrés Román ivorra³, ¹Hospital Universitario de La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ³Hospital Universitari i Politécnic La Fe, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, València, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital Universitario de La Fe, València, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain
Background/Purpose: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral…
Abstract Number: 1325 • ACR Convergence 2022
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
Adil Vural¹, Sarah Keller², Neel Tapryal³, Komal Mushtaq⁴, Hassan Shaheen¹, Chao Zhang², Marie Budev², Abby Abelson² and Chad Deal⁵, ¹Cleveland Clinic, Westlake, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Rocky River, OH, ⁴Cleveland Clinic, Fairview Park, OH, ⁵Cleveland Clinic, Shaker Heights, OH
Background/Purpose: Osteoporotic fractures are a well-known complication of lung transplant (LT) and can significantly impact the quality of life of LT recipients. Although much is…
Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1146 • ACR Convergence 2021
Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting
Zareen Vaghaiwalla¹, Paul Wasserman¹ and Gurjit Kaeley², ¹University of Florida College of Medicine Jacksonville, Jacksonville, FL, ²University of Florida, Jacksonville, FL
Background/Purpose: Patients with osteoporosis are prone to suffer fragility fractures leading to an increased risk of future fractures. Detection of osteoporosis has been led by…
Abstract Number: 1147 • ACR Convergence 2021
Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
Shiva Malaty, Paramvir Sidhu, Rustan Sharer and Soo Yeon Kim, HonorHealth Internal Medicine Residency, Scottsdale, AZ
Background/Purpose: Treatment rates with pharmacologic therapy after osteoporotic vertebral fracture are very low in the United States. Underlying causes of these low treatment rates are…
Abstract Number: 1148 • ACR Convergence 2021
Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases
Bjoern Buehring¹, Nadine Al-Azem¹, Ioana Andreica¹, David Kiefer², Uta Kiltz¹, Styliani Tsiami¹, Xenofon Baraliakos¹ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: Unlike fragility fractures, high-trauma and insufficiency fractures (IF) are not classically considered osteoporotic fractures. Patients with rheumatic and musculoskeletal diseases (RMD), especially those with…
Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…
Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
Abstract Number: 1017 • ACR Convergence 2021
Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine¹, Jacob R. Jones¹, Marc Nuzzo¹, Lidsay N. Schnur² and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Dendritic Cell (DC)-Specific Transmembrane Protein (STAMP) expressed by osteoclast precursors is required for cell-cell fusion in the formation of the osteoclast (OC) polykaryon. Genetic…
Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 0128 • ACR Convergence 2020
Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck
Rosachiara Forcignanò¹, Fiorella Anna Lombardi², Mariangela Ciccarese³, Eugenio Quarta⁴, Antonella Grimaldi⁵, Laura Quarta⁵, Delia Ciardo², Ernesto Casciaro², Paola Pisani², Francesco Conversano², Maurizio Muratore⁵ and Sergio Casciaro², ¹O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, ²National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, ³O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, ⁴O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, ⁵O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy
Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health…
Abstract Number: 0129 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Sandra Hermann¹, Robert Biesen³ and Frank Buttgereit⁴, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁴Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well…
Abstract Number: 0130 • ACR Convergence 2020
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
Timothy Varghese¹, Ali Ahmadi Pirshahid², Dongkeun Kim² and Yueyang Li², ¹Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, ²Schulich School of Medicine & Dentistry, London, ON, Canada
Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].